Frequency of ERG-Positive prostate carcinoma in Poland

Polish Journal of Pathology

Volumn 64, Issue 3, 2013, Pages 175-179

  Kaczmarczyk, Kaolina ^a   Dyduch, Grzegorz ^a   Białas, Magdalena ^a   Demczuk, Sergiusz ^a   Szopiński, Tomasz ^a   Chłosta, Piotr ^a   Okoń, Krzysztof ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

ERG; Immunohistochemistry; Prostatic carcinoma; Tissue microarray

Indexed keywords

EID: 84886006047     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: 10.5114/PJP.2013.38134     Document Type: Article

References (25)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TM- PRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-648.
3. Park K, Tomlins SA, Mudaliar KM, et al. Antibody-Based Detection of ERG Rearrangement-Positive Prostate Cancer. Neoplasia 2010; 12: U590-U595.
4. Falzarano SM, Zhou M, Carver P, et al. ERG gene rearrangement status in prostate cancer detected by immunohistochemistry. Virchows Arch 2011; 459: 441-447.
5. van Leenders GJ, Boormans JL, Vissers CJ, et al. Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice. Mod Pathol 2011; 24: 1128-1138.
6. Mao X, Yu Y, Boyd LK, et al. Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis. Cancer Res 2010; 70: 5207-5212.
7. Lee K, Chae JY, Kwak C, et al. TMPRSS2-ERG gene fusion and clinicopathologic characteristics of Korean prostate cancer patients. Urology 2010; 76: 1268.e1267-1213.
8. Luczynska E, Gasinska A, Wilk W. Microvessel density and expression of vascular endothelial growth factor in clinically localized prostate cancer. Pol J Pathol 2013; 64: 33-38.
9. Epstein JI, Allsbrook WCJr., Amin MB, et al. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005; 29: 1228-1242.
10. Fine SW, Amin MB, Berney DM, et al. A contemporary update on pathology reporting for prostate cancer: Biopsy and radical prostatectomy specimens. Eur Urol 2012; 62: 20-39.
11. Furusato B, Tan SH, Young D, et al. ERG oncoprotein expression in prostate cancer: Clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis 2010; 13: 228-237.
12. Perner S, Mosquera JM, Demichelis F, et al. TMPRSS2-ERG fusion prostate cancer: An early molecular event associated with invasion. Am J Surg Pathol 2007; 31: 882-888.
13. Verdu M, Trias I, Roman R, et al. ERG expression and prostatic adenocarcinoma. Virchows Arch 2013; 462: 639-644.
14. Szász AM, Majoros A, Rosen P, et al. Prognostic potential of ERG (ETS-related gene) expression in prostatic adenocarcinoma. Int Urol Nephrol 2013; 45: 727-733.
15. Teng LH, Wang C, Begin LR, et al. ERG protein expression and gene rearrangements are present at lower rates in metastatic and locally advanced castration-resistant prostate cancer compared to localized disease. Urology 2013; 82: 394-399.
16. Fine SW, Gopalan A, Leversha MA, et al. TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features. Mod Pathol 2010; 23: 1325-1333.
17. Albadine R, Latour M, Toubaji A, et al. TMPRSS2-ERG gene fusion status in minute (minimal) prostatic adenocarcinoma. Mod Pathol 2009; 22: 1415-1422.
18. Suh JH, Park JW, Lee C, et al. ERG immunohistochemistry and clinicopathologic characteristics in Korean prostate adenocar-cinoma patients. Korean J Pathol 2012; 46: 423-428.
19. Kimura T, Furusato B, Miki J, et al. Expression of ERG oncoprotein is associated with a less aggressive tumor phenotype in Japanese prostate cancer patients. Pathol Int 2012; 62: 742-748.
20. Wu F, Ding S, Lu J. Truncated ERG proteins affect the aggressiveness of prostate cancer. Med Hypotheses 2013; 80: 490-493.
21. Gasi Tandefelt D, Boormans JL, van der Korput HA, et al. A 36- gene signature predicts clinical progression in a subgroup of ERG-positive. Eur Urol 2013; 10.1016/j.eururo.2013.02.039.
22. Shah RB. Clinical applications of novel ERG immunohistochemistry in prostate cancer diagnosis and management. Adv Anat Pathol 2013; 20: 117-124.
23. Yaskiv O, Zhang X, Simmerman K, et al. The utility of ERG/P63 double immunohistochemical staining in the diagnosis of limited cancer in prostate needle biopsies. Am J Surg Pathol 2011; 35: 1062-1068.
24. Tomlins SA, Palanisamy N, Siddiqui J, et al. Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies. Arch Pathol Lab Med 2012; 136: 935-946.
25. Shah RB, Tadros Y, Brummell B, et al. The diagnostic use of ERG in resolving an atypical glands suspicious for cancer diagnosis in prostate biopsies beyond that provided by basal cell and alpha-methylacyl-CoA-racemase markers. Hum Pathol 2013; 44: 786-794.